PhRMA
AUGUST 8, 2022
Despite having insurance, too many patients with HIV face high out-of-pocket costs for brand medicines. This is largely driven by insurer-imposed barriers that shift the cost of life-saving care onto patients.
Pharmacy Times
AUGUST 8, 2022
Investigators found that the health risks linked to the condition known as metabolic syndrome could be diminished by green tea’s anti-inflammatory benefits in the gut.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 8, 2022
A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes. The finding comes from the large-scale CONNECT-HF cluster study, which looked at various patient engagement and education interventions to see if they could help patients with heart failure do better after discharge from hospital.
Pharmacy Times
AUGUST 8, 2022
Use of hormone therapy to treat prostate cancer may require more consideration by health care providers as new study shows the therapy may increase the risk of heart disease.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
AUGUST 8, 2022
Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.
Pharmacy Times
AUGUST 8, 2022
Health care workers who got 4 total doses against COVID-19, 2 doses of which are boosters, experienced more than 10% lower breakthrough infection rate than those with only 3 total doses.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 8, 2022
Preliminary data from the ongoing dose-escalation portion of the clinical trial, show dose-dependent anti-tumor activity when combined with standard-dose Libtayo.
Pharmaceutical Technology
AUGUST 8, 2022
The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients. The latest approval is based on positive data from the multicentre, double-blind, randomised, placebo-controlled Phase III ARASENS clinical trial that analysed the safety and efficacy of oral darolutamide plus androgen deprivation therapy (ADT) an
Pharmacy Times
AUGUST 8, 2022
Genetic variations in the 5-hydroxytryptamine serotonin receptor uniquely impacted the receptor’s response to psychedelic drugs, including LSD and psilocin, possibly explaining why patients have varied success with psychedelic treatment for psychiatric conditions.
European Pharmaceutical Review
AUGUST 8, 2022
Eight years after the whistle was blown on Eli Lilly for allegedly underpaying the rebates required of drug manufacturers under the US Medicaid Drug Rebate Program, a jury has ordered the company to pay more than $61 million in damages. However, as the whistleblower Ronald J Streck filed a False Claims Act lawsuit, the damages will be trebled and the final judgment will be over $183 million, according to Streck’s legal team.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 8, 2022
The median overall survival of the lenvatinib monotherapy arm is longer than that observed in previous clinical trials evaluating it as a monotherapy for unresectable hepatocellular carcinoma.
Outsourcing Pharma
AUGUST 8, 2022
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
Pharmacy Times
AUGUST 8, 2022
Unlike prior recommendations for prevention, which focus on dietary factors associated with first-time stone formulation, the new analysis looks at recurrences.
PharmExec
AUGUST 8, 2022
Seasoned executive brings expertise with high-growth companies as pharma programmatic advertising spending dramatically increases.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 8, 2022
Revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology, aligning with the Department of Health and Human Services’ roadmap.
Pharmaceutical Technology
AUGUST 8, 2022
The US Food and Drug Administration (FDA) has granted approval for Pfizer and Myovant Sciences ’ Myfembree (relugolix 40mg, estradiol 1mg and norethindrone acetate 0.5mg) to manage moderate-to-severe pain linked with endometriosis in pre-menopausal women. Myfembree is a one-pill treatment indicated to be administered once daily for a treatment period of up to 24 months.
Pharmacy Times
AUGUST 8, 2022
The CDC published a new study, which found that a second mRNA booster shot would be effective against the Omicron variants of COVID-19.
pharmaphorum
AUGUST 8, 2022
Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ($3.1 billion) blockbuster. The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier indication in non-metastatic castration-resistant prostate cancer (nmCRPC).
Pharmacy Times
AUGUST 8, 2022
In addition to expanding patient access to Paxlovid, the recent authorization of pharmacists to prescribe the drug marks a step toward provider status.
PQA
AUGUST 8, 2022
This guest blog is one in a series by sponsors of the 2022 PQA Annual Meeting on the utilization of the EQUIPP platform to promote performance improvement on medication-related quality measures while engaging transparency between health plans and pharmacies. The views shared in this series are those of the author and do not reflect any PQA positions.
Pharmacy Times
AUGUST 8, 2022
The B-Clear study investigated the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in individuals with chronic hepatitis B.
Pharmaceutical Commerce
AUGUST 8, 2022
Medication access solutions should be curated to the specific needs of the medication and patients themselves. Read more about medication access, affordability and adherence capabilities in the CoverMyMeds Solutions Overview.
Pharmacy Times
AUGUST 8, 2022
A new neutralizing monoclonal antibody could become an inhaled cocktail for long-term COVID-19 prevention.
pharmaphorum
AUGUST 8, 2022
Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. KarXT is an oral, investigational muscarinic agonist comprised of the muscarinic agonist xanomeline and muscarinic antagonist trospium, developed for treating psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Pharmacy Times
AUGUST 8, 2022
The approval is based on results of the phase 3 study, ARASENS, that demonstrated a statistically significant increase in overall survival, the trial’s primary endpoint.
Pharmaceutical Technology
AUGUST 8, 2022
The proportion of pharmaceutical companies hiring for future of work related positions rose in July 2022 compared with the equivalent month last year, with 48.5% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 42.9% of companies who were hiring for future of work related jobs a year ago and an increase compared to the figure of 46.6% in June 2022.
Pharmacy Times
AUGUST 8, 2022
Dalteparin sodium (Fragmin) is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce VTE recurrence in adult patients with cancer, as well as several other indications.
pharmaphorum
AUGUST 8, 2022
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that was once lumped under the HER2-negative classification. It has the potential to be a sizeable new indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate, and central to AZ and Daiichi Sankyo’s hopes of unlocking multibillion-dollar sales for the drug.
Pharmacy Times
AUGUST 8, 2022
Based on overall response rate, acalabrutinib in tablet form is now FDA approved for all approved indications, enabling co-administration alongside a proton pump inhibitor.
pharmaphorum
AUGUST 8, 2022
Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports. A deal could be announced as early as today, when GBT is scheduled to report its second quarter results, according to a Wall Street Journal report citing people familiar with the matter.
Pharmacy Times
AUGUST 8, 2022
With limited supply to immunization options for monkeypox, polio, and influenza, the future of vaccine distribution will have to change.
pharmaphorum
AUGUST 8, 2022
Mark Doyle, co-founder of The Method and creator of the A Life in a Day programme, tells us about the immersive experience he and his team created that allows anyone to live the life of a type 2 diabetes patient for 24 hours. Approximately 422 million people worldwide live with diabetes, the majority suffering from type 2 diabetes, but many healthcare professionals don’t understand the full extent of what it’s like to live day-to-day as a diabetes patient. “In 2015, we were app
PharmExec
AUGUST 8, 2022
National healthcare consultancy and marketing firm hires Senior Vice President of Business Development to meet growing market demand and client partnership opportunities.
Outsourcing Pharma
AUGUST 8, 2022
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
Expert insights. Personalized for you.
162 
Let's personalize your content